Our two phase 2 stage first-in-class and novel mode of action drug candidates are pipeline generators as they each have multiple indications potential (“I&I pipeline in a product”):

MC2-32: Oral HSP90 Inhibitor with a unique specific tissue targeting profile modulating multiple pro-inflammatory pathways and relevant immune responses with a uniquely favorable safety profile.

MC2-25: Iso-cyanate Scavenger addressing non-enzymatic posttranslational protein and amino acid modification (carbamylation) in the skin by iso-cyanate, a dissociation product of urea.

We are currently pursuing indications where there are no or very limited approved treatment options including oral MC2-32 for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 for Vulvar Lichen Sclerosus (Ph2a ongoing).

We are applying our expertise in formulation and clinical practice release of the full clinical potential of therapies and ensure treatment satisfaction for patients.